Infliximab for laryngopharyngeal involvement in Behçet’s syndrome

Clicks: 1
ID: 320555
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #10 of 43 articles by views in Modern Rheumatology Case Reports

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Laryngopharyngeal involvement in Behçet’s syndrome is rare but clinically significant because it may cause severe odynophagia, dysphagia, and airway compromise. Optimal treatment has not been established, and irreversible structural sequelae, including laryngopharyngeal stenosis and ulcer scarring, may occur. We describe two men with Behçet’s syndrome and symptomatic laryngopharyngeal involvement who showed rapid improvement after infliximab administration following an insufficient response to corticosteroids. In case 1, a 25-year-old man was classified as having suspected Behçet’s syndrome based on recurrent oral ulcers, pharyngeal ulceration, arthritis, folliculitis-like skin lesions, and previous episodes of abdominal pain. He developed severe pharyngeal pain and dysphagia due to ulcerative lesions extending from the posterior pharyngeal wall to the esophageal inlet. Intravenous prednisolone resulted in limited endoscopic and symptomatic improvement, whereas infliximab promptly relieved pain and restored oral intake, with no recurrence over 14 years of follow-up. In case 2, a 29-year-old man presented with recurrent fever, oral aphthae, genital ulcers, arthritis, erythema nodosum-like lesions, and pharyngeal and laryngeal mucosal lesions associated with dysphagia. His symptoms and laryngoscopic abnormalities improved promptly after infliximab administration following an inadequate response to prednisolone. These cases underscore the importance of considering early anti-tumor necrosis factor-α therapy in steroid-refractory or relapsing laryngopharyngeal Behçet’s syndrome, because progression to irreversible structural complications, including stenosis and adhesion, may necessitate surgical intervention if inflammation is not controlled before permanent damage occurs.
Reference Key
openalex_W7167941515 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors M. Wakatsuki, Hiroyuki Yamashita, Hiroshi Kaneko
Journal Modern Rheumatology Case Reports
Year 2026
DOI
10.1093/mrcr/rxag068
URL
https://doi.org/10.1093/mrcr/rxag068
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.